A Phase 4 interventional study of Sertraline, bupropion, desvenlafaxine in Major Depressive Disorder, Neuroticism and Cognitive Change, sponsored by David Steffens. Active, not recruiting at 1 site in United States. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2026-05-22.
Sponsored by David Steffens · Phase 4, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 44 studies testing sertraline in Depressive Disorder, Major — 6 open to participants now, 7 under way, none of them phase 3. Sertraline · Depressive Disorder, Major.
Among the 44 studies testing sertraline in Depressive Disorder, Major, this one is the 23rd largest by planned enrollment, is the only one that started in 2021, is one of 16 in phase 4, and was the 35th registered.
3,051 studies on the registry are indexed under Depressive Disorder, Major; 596 are open to participants now.
Browse Depressive Disorder, Major studies →6 of the 44 studies testing sertraline in Depressive Disorder, Major are open now, in 4 countries. Recruiting first, the newest first:
First Affiliated Hospital of Chongqing Medical University · Sites in China
Ages 12–18
First Affiliated Hospital of Chongqing Medical University · Sites in China
Ages 12–18
University of Bern · Sites in Zimbabwe
Ages 18+
Poznan University of Medical Sciences · Sites in Poland
Ages 12+
University of Texas at Austin · Sites in United States
Ages 18–65
By country, each count listing its studies:
Sertraline: first FDA approval 1991 (ZOLOFT). What it is approved for, and how studies give it, is on its page →
Of the 419 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 299 (71%) stop at 75 or younger; 55 take children under 18; 100 take healthy volunteers.
This study: 65 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
44 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 9 · Phase 3 7 · Phase 4 16
First in 1998; this study’s year is marked. 1 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 75 is close to the median of 80 across 2,535 interventional studies indexed under Depressive Disorder, Major.
Median enrollment 78 across the 44 interventional studies. Of the 31 that completed or were terminated, 12 (39%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 44 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with David Steffens as lead sponsor.
David Steffens has 1 study filed under Depressive Disorder, Major — fewer than ten, so there is no comparison to draw.
4 of the studies testing sertraline in Depressive Disorder, Major that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05273996David SteffensPredictors of Cognitive Outcomes in Geriatric Depression | 2027-04-30 |
| NCT07011693Xinyu ZhouSwitching Medication and Augmentation Strategies for SSRI-Resistant Adolescent Depression(SMART-I) | 2027-06 |
| NCT05892744University of Texas at AustinEstablishing Multimodal Brain Biomarkers for Treatment Selection in Depression | 2027-07-15 |
| NCT07478796Poznan University of Medical SciencesTDM-Guided Treatment With SSRIs in Hospitalized Adults and Children | 2027-11-30 |
Add all 4 to your calendar (.ics) → With an account.
Among the 44 studies testing sertraline in Depressive Disorder, Major, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study will focus on examining effects of stress on long-term mood and cognitive outcomes of late-life depression. It will also example the neural underpinnings of these changes using structural and functional brain imaging. Understanding how effects of stress in older depressed adults, as well as factors that might minimize those effects, lead to particular mood and cognitive outcomes will inform future development of novel prevention strategies.
In this renewal of R01MH108578, the investigators are seeking to extend findings from the initial study to focus on effects of stress in longitudinal mood and cognitive outcomes of late-life depression (LLD) and to examine stress effects on brain structure and function in LLD. Severe or persistent stressors can result in a number of behavioral and mood changes, including anxiety, dysphoric mood, sleep disruption, altered appetite, and withdrawal from social and pleasurable activities. These stress-related consequences are particularly salient when considering longitudinal outcomes of treated LLD. They may be compounded by an individual's longstanding maladaptive patterns of response to stress, embodied in the construct of neuroticism, which the investigators have shown to be related to poor mood and cognitive LLD outcomes. Moreover, Andreescu et al. (2019) introduced a model of depression recurrence that incorporates the homeostatic disequilibrium hypothesis, which proposes that in geriatric remitted depression, neural networks are in fragile homeostasis that is threatened by stress exposure. Networks of particular importance in stress of LLD outcome are the Default Mode Network (DMN), Salience Network (SN) and Executive Control Network (ECN).
The Neurobiology of Late Life Depression (NBOLD) study began enrolling older depressed and never depressed controls in 2013, enrolling 132 depressed and 44 controls, and currently follows 77 depressed and 22 controls. Subjects are well characterized in terms of mood, cognition, personality and stress (including specific measures obtained during the present COVID pandemic). It is well suited to examine stress effects on longitudinal mood and cognitive outcomes. For the renewal, the study will follow current subjects and recruit 75 new subjects, who will be followed for up to 5 years with annual cognitive testing, stress measures and baseline and two-year functional brain magnetic resonance imaging (fMRI) scan.
In this renewal, the investigators will examine the following specific aims:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects receive FDA-approved antidepressants
Drug: Sertraline, bupropion, desvenlafaxine
Drug pages: SertralineStudies of SertralineSertraline pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · BupropionStudies of BupropionBupropion pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · DesvenlafaxineStudies of DesvenlafaxineDesvenlafaxine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
Study geriatric psychiatrists prescribe FDA-approved antidepressants using a treatment algorithm consistent with the STAGED (Duke Somatic Treatment Algorithm for Geriatric Depression) approach, with standardization of treatment in the first six months beginning with sertraline, with the option of augmentation with bupropion or switch to desvenlafaxine. Beyond six months of acute treatment, subjects are treated based on the study psychiatrist's clinical assessment and recommendations, consistent with STAGED guidelines.
Also known as: Zoloft, Wellbutrin, Pristiq
Montgomery-Asberg Depression Rating Scale (MADRAS)
Measure of depression severity and Recurrence of Depression Minimum Score = 0; Maximum Score = 60; Higher score means worse outcome
Time frame: Three years
Consortium to Establish a Registry for Alzheimer's Disease (CERAD) Neuropsychological Battery Total Score
Global cognitive measure; Minimum Score = 0; Maximum Score = 100; Higher score means better outcome
Time frame: Three years
Cognitive clinical diagnosis
Participant records will be reviewed annually by the consensus panel. The study will convene a panel of experts to review each case, including the PI, treating geriatric psychiatrists and study neuropsychologist. Panel members review the following information for each participant: 1) initial evaluation and most recent clinical depression study notes, 2) neuropsychological testing profiles, 3) informant report of cognitive decline based on the Dementia Severity Rating Scale, 4) study structural MRI images to determine vascular burden, and 5) additional neurological and clinical neuropsychological consultations when available. The panel discusses the case until a consensus cognitive diagnosis is reached.
Time frame: three years
Functional brain magnetic resonance imaging (fMRI) scan changes in resting state functional connectivity.
A change in the strength of connectivity within a network and between two networks will be determined by comparing the strength of connectivity at baseline and at two years. The functional connectivity strength is reflected by a z score of normalized Pearson correlation coefficient using the Fisher transformation.
Time frame: Two years
Functional brain magnetic resonance imaging (fMRI) scan structural imaging changes
Measures from structural imaging in the key brain regions will be the volumetric measurement from T1-weighted MRI. A change in the volume of a brain structure will be determined by subtracting the regional volume at baseline from two years.
Time frame: Two years
Neuroticism subtest score on NEO Personality Inventory
Neuroticism domain and its subdomains will be examined; Minimum Score = 0; Maximum Score = 92; Higher score means worse outcome
Time frame: Three years
Plan to share: Yes — This R01 will develop important new data on 75 subjects. These data will be available to investigators both within UConn and outside the institution.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form
Time frame: Starting 6 months after publication
Access criteria: Potential investigators will gain knowledge of the project through NIH Reporter and through Dr. Steffens' UConn webpage. They will be able to contact Dr. Steffens and he will work with the investigator to determine the nature of what the investigator wishes to study to ensure that he/she has a complete data set that will allow for a successful analysis. Dr. Steffens' team will create an anonymized data set, encrypt it, and electronically transfer it to the investigator. Dr. Steffens will maintain a list of approved analyses and track progress of manuscripts and publications. In addition, consistent with National Institute of Mental Health (NIMH)requirements, Dr. Steffens will plan to submit data via the NIMH Data Archive (NDA).
No publications or documents are linked to this record.
Started Sep 2021 (actual). Primary completion is estimated for Apr 2027, 67 months after the start.
Of 79 non-industry phase 4 interventional studies under Depressive Disorder, Major, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 60. This study's planned 67 months is above that.
Counting every sponsor, half of 98 studies reached it within 35 months; a quarter within 20 and three quarters within 58.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Sertraline · Bupropion · Desvenlafaxine